NCT03548103: GEOP

Green Tea Extract for Obesity of Psychiatric Patients

Completed NA Last updated 12 April 2023

What this trial tests

NA trial testing Green tea extract in Obesity in 45 participants. Completed in 31 March 2020.

Timeline

20 May 2018

Primary endpoint
31 December 2019

31 March 2020

Quick facts

Lead sponsor	Taipei City Hospital
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	45
Start date	20 May 2018
Primary completion	31 December 2019
Estimated completion	31 March 2020
Sites	1 location across Taiwan

Drugs / interventions tested

• Green tea extract — full drug profile →
• Placebo

Conditions studied

• Obesity — all drugs for Obesity →
• Metabolic Syndrome — all drugs for Metabolic Syndrome →

Sponsor

Taipei City Hospital

Who can join

Adults 20 to 65, any sex, with Obesity or Metabolic Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Obesity or metabolic syndrome is becoming a global epidemic and common health problem, leading to the increase of associated comorbidities such as type 2 diabetes, cardiovascular disease, and certain cancers. This phenomenon is also a serious problem among psychiatric patients due to the increase use of second generation antipsychotics and mood stabilizers such as lithium or valproic acid. These metabolic abnormalities can be regarded as medical comorbidities, and have an impact not only on physical health and increased hospital length of stay, but also on a lower functional outcome, low self-esteem and poorer quality of life and non-compliance to antipsychotics. Green tea is one of the most popular beverages in the world and is believed to have beneficial effects in prevention and treatment of many diseases, such as cancer-prevention, adjunct to chemotherapy for malignancy, to reduce mental and physical stress and improve memory function, to increase bone mineral density, and to decrease body weight. Since weight gain is a common and undesirable side effect with psychiatric medications, the management of it becomes an important issue in clinical practice. In this clinical trial, we will use decaffeinated green tea extract to treat overweight patients with schizophrenia or bipolar disorder in a double-blind, placebo-controlled study design.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.